Nilmat (Nilotinib)

Nilotinib selectively blocks the BCR‑ABL tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome translocation. By occupying the ATP‑binding pocket of BCR‑ABL, it stops downstream signaling that promotes uncontrolled growth of leukemic cells, leading to reduced proliferation and increased cell death of the malignant clone.

The dose of Nilmat is individualized by the prescribing physician based on the patient’s disease status, tolerability, and other clinical factors. Healthcare professionals determine the appropriate strength, frequency, and duration of therapy according to current treatment guidelines and patient-specific considerations.

Safety data for nilotinib during pregnancy and lactation are limited. The drug is generally not recommended for use in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant. Women of childbearing potential should use effective contraception during treatment and for a period after discontinuation.

To request Nilmat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Nilmat (nilotinib) and imatinib are both BCR‑ABL tyrosine kinase inhibitors used for CML. Nilotinib is a second‑generation TKI with higher potency and activity against many imatinib‑resistant mutations, but it may carry a higher risk of QT prolongation. Choice of therapy depends on mutation profile, prior treatment response, and individual patient risk factors.

Nilmat tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Keep the product away from moisture, direct sunlight, and excessive heat. Do not store in bathrooms or near kitchen appliances. Ensure the packaging remains sealed until use to maintain product integrity.

Nilmat is taken orally, usually with a glass of water. It can be taken with or without food, but patients should avoid high‑fat meals that may affect absorption. The tablets should be swallowed whole; they should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious adverse events associated with Nilmat include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe liver injury, and pancreatitis. Patients should report any symptoms such as palpitations, chest pain, jaundice, severe abdominal pain, or persistent nausea to their physician promptly.

Nilmat is contraindicated in individuals with known hypersensitivity to nilotinib or any of its excipients, patients with a history of prolonged QT interval, and those with severe hepatic impairment. Caution is also advised for patients with uncontrolled cardiovascular disease or significant electrolyte disturbances.